ArticleScientific reports2025
Serum β2-microglobulin level is associated with the survival of HIV-associated diffuse large B-cell lymphoma: a retrospective study from China.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A deep learning-based prognostic model for diffuse large B-cell lymphoma incorporating PET/CT imaging features.Frontiers in oncology · 2026Article
- Dynamic changes in serum IL-6, TNF-Frontiers in medicine · 2026Article
- LDH to lymphocyte percentage ratio is a novel predictor of in-hospital mortality in PLWH - a retrospective study.BMC infectious diseases · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
HIV-associated diffuse large B-cell lymphoma (DLBCL) is a rare type of lymphoma with poor prognosis. β2-microglobulin (β2-M) is elevated in people living with HIV, but its prognostic significance in HIV-associated DLBCL remains unclear. We retrospectively analyzed 89 HIV-associated DLBCL patients treated at Chongqing University Cancer Hospital between October 2012 and December 2023. The primary outcome was the clinical overall survival (OS) rate. The optimal cut-off value of β2-M was determined to be 5 mg/L. Compared to the low serum β2-M group (< 5 mg/L), patients in the high serum β2-M group (≥ 5 mg/L) had a higher International Prognostic Index (IPI)/ age adjusted IPI (aaIPI) score, more B symptoms, lower CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.